TY  - JOUR
AU  - Garcia-Alfonso, Pilar
AU  - Benavides, Manuel
AU  - Falco, Esther
AU  - Muñoz, Andres
AU  - Gomez, Auxiliadora
AU  - Sastre, Javier
AU  - Rivera, Fernando
AU  - Montagut, Clara
AU  - Salgado, Mercedes
AU  - Lopez-Ladron, Amelia
AU  - Lopez, Rafael
AU  - Ruiz de Mena, Inmaculada
AU  - Duran, Gema
AU  - Aranda, Enrique
PY  - 2018
DO  - 10.1634/theoncologist.2018-0316
UR  - http://hdl.handle.net/10668/12849
T2  - The oncologist
AB  - RAS- or BRAF-mutated metastatic colorectal cancers (mCRCs) progressing after first-line treatment have a poor prognosis.European and U.S. guidelines include the multikinase inhibitor regorafenib as a standard option for second-line therapy and beyond,...
LA  - en
PB  - Oxford University Press
KW  - Área de Gestión Sanitaria Sur de Sevilla
KW  - Antineoplastic agents, immunological
KW  - Antineoplastic combined chemotherapy protocols
KW  - Bevacizumab
KW  - Camptothecin
KW  - Colorectal neoplasms
KW  - Female
KW  - Fluorouracil
KW  - Humans
KW  - Leucovorin
KW  - Male
KW  - Mutation
KW  - Neoplasm metastasis
KW  - Organoplatinum compounds
KW  - Phenylurea compounds
KW  - Proto-oncogene proteins B-raf
KW  - Pyridines
KW  - ras proteins
TI  - Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).
TY  - research article
VL  - 23
ER  -